

Tapan K Bera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6596690/publications.pdf>

Version: 2024-02-01

30
papers

1,134
citations

471061

17
h-index

476904

29
g-index

30
all docs

30
docs citations

30
times ranked

1671
citing authors

#	ARTICLE	IF	CITATIONS
1	Mesothelin Is Not Required for Normal Mouse Development or Reproduction. <i>Molecular and Cellular Biology</i> , 2000, 20, 2902-2906.	1.1	198
2	MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6997-7002.	3.3	116
3	A model for obesity and gigantism due to disruption of the <i>Ankrd26</i> gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 270-275.	3.3	79
4	POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16975-16980.	3.3	75
5	NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 3059-3064.	3.3	74
6	Recombinant Immunotoxins in the Treatment of Cancer. , 2004, 248, 503-518.		70
7	POTE Paralogs Are Induced and Differentially Expressed in Many Cancers. <i>Cancer Research</i> , 2006, 66, 52-56.	0.4	59
8	Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3501-E3508.	3.3	44
9	Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths. <i>Gene</i> , 2004, 337, 45-53.	1.0	43
10	PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3058-3063.	3.3	38
11	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 685-694.	1.6	37
12	PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon. <i>Prostate</i> , 2001, 47, 125-131.	1.2	36
13	An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. <i>Leukemia Research</i> , 2014, 38, 1224-1229.	0.4	34
14	Cse1l Is Essential for Early Embryonic Growth and Development. <i>Molecular and Cellular Biology</i> , 2001, 21, 7020-7024.	1.1	32
15	GDEP, a new gene differentially expressed in normal prostate and prostate cancer. <i>Prostate</i> , 2001, 48, 231-241.	1.2	31
16	Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1648-1655.	1.9	22
17	Selective POTE Paralogs on Chromosome 2 are Expressed in Human Embryonic Stem Cells. <i>Stem Cells and Development</i> , 2008, 17, 325-332.	1.1	19
18	Comparison of Recombinant Immunotoxins against LeYAntigen Expressing Tumor Cells:Â Influence of Affinity, Size, and Stability. <i>Bioconjugate Chemistry</i> , 1998, 9, 736-743.	1.8	17

#	ARTICLE	IF	CITATIONS
19	POTE protein, a cancer-testis antigen, is highly expressed in spermatids in human testis and is associated with apoptotic cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 1271-1274.	1.0	15
20	Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 4592-4598.	3.3	14
21	Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 812-821.	1.9	14
22	Immunotherapy-based targeting of MSLN activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	11
23	Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. <i>Toxins</i> , 2018, 10, 447.	1.5	8
24	Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. <i>Toxins</i> , 2018, 10, 210.	1.5	8
25	Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice. <i>PLoS ONE</i> , 2014, 9, e104388.	1.1	8
26	Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2202439119.	3.3	8
27	Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma. <i>Antibody Therapeutics</i> , 2018, 1, 19-25.	1.2	7
28	Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 192-199.e1.	1.0	7
29	Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation. <i>Biomolecules</i> , 2020, 10, 1387.	1.8	6
30	Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy. <i>Journal of Immunotherapy</i> , 2019, 42, 119-125.	1.2	4